Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for protein-protein interfaces.
Fig. 1. The sreening workflow of Receptor.AI
It features thorough molecular simulations of the target protein, both isolated and in complex with key partner proteins, complemented by ensemble virtual screening that accounts for conformational mobility in the unbound and complex states. The tentative binding sites are explored on the protein-protein interaction interface and at remote allosteric locations, encompassing the entire spectrum of potential mechanisms of action.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9UK53
UPID:
ING1_HUMAN
Alternative names:
-
Alternative UPACC:
Q9UK53; O00532; O43658; Q53ZR3; Q5T9G8; Q5T9G9; Q5T9H0; Q5T9H1; Q9H007; Q9HD98; Q9HD99; Q9NS83; Q9P0U6; Q9UBC6; Q9UIJ1; Q9UIJ2; Q9UIJ3; Q9UIJ4; Q9UK52
Background:
Inhibitor of growth protein 1 plays a pivotal role in cell cycle regulation and apoptosis, acting as a co-regulator of p53, a well-known tumor suppressor. Its involvement in modulating p53-dependent transcriptional activation underscores its significance in cellular homeostasis.
Therapeutic significance:
Given its critical function in the negative regulatory pathway of cell growth and its implication as a tumor suppressor gene, Inhibitor of growth protein 1 is directly linked to Squamous cell carcinoma of the head and neck. This association highlights its potential as a target for therapeutic intervention in non-melanoma skin cancer.